Vivesto AB announced that the Board of Directors of the company has appointed Erik Kinnman as CEO of the company. Erik Kinnman will assume the position as CEO no later than 20 May 2023. Erik Kinnman is a physician, Ph.D., with specialist training in neurology and pain management, a Doctor of Medicine and an associate professor at Karolinska Institutet, and holds an Executive MBA from the Stockholm School of Economics.

Erik has 25 years of experience from senior positions within Life Science and is currently a Board member of Stayble Therapeutics and Immune System Regulation and the CEO of Sprint Bioscience. He has previously been the CEO of Abliva AB (formerly Neurovive) and has held senior positions at AstraZeneca and Sobi, among others, and worked as a financial analyst at Danske Bank. Erik does not own any shares or share-related instruments in Vivesto.